Dr Bruce Wong’s career in neuroscience has concentrated on ageing and neurodegenerative diseases, with a particular emphasis on Alzheimer’s disease. He began his postdoctoral tenure at the Florey Institute of Neuroscience and Mental Health, collaborating with Professor Ashley Bush and Dr James Duce, both of whom are distinguished experts in neurodegenerative research. In this role, Dr Wong explored the involvement of transition metals in the pathological mechanisms underlying ageing and neurodegeneration.
Subsequently, Dr Wong temporarily relocated to the United Kingdom to serve as a biology team project leader at the ALBORADA Drug Discovery Institute, University of Cambridge. There, he managed and contributed to the preclinical development of biopharmaceuticals targeting neurodegenerative disorders. Following three years of valuable industry experience in the UK—and through a collaborative initiative between the University of Cambridge and the University of Melbourne—he returned to Australia to join Professor Peter Crack’s Laboratory as a Research Fellow. Drawing on his combined expertise from both academic and industry settings, Dr Wong now investigates inflammatory pathways in the brains of individuals with neurodegenerative diseases, focusing on the development of small molecule screens and therapeutics aimed at mitigating disease aetiology.
Dr Bruce Wong’s career in neuroscience has concentrated on ageing and neurodegenerative diseases, with a particular emphasis on Alzheimer’s disease. He began his postdoctoral tenure at the Florey Institute of Neuroscience and Mental Health, collaborating with Professor Ashley Bush and Dr James Duce, both of whom are distinguished experts in neurodegenerative research. In this role, Dr Wong explored the involvement of transition metals in the pathological mechanisms underlying ageing and neurodegeneration.
Subsequently, Dr Wong temporarily relocated to the United Kingdom to serve as a biology team project leader at the ALBORADA Drug Discovery Institute, University of Cambridge. There, he managed and contributed to the preclinical development of biopharmaceuticals targeting neurodegenerative disorders. Following three years of valuable industry experience in the UK—and through a collaborative initiative between the University of Cambridge and the University of Melbourne—he returned to Australia to join Professor Peter Crack’s Laboratory as a Research Fellow. Drawing on his combined expertise from both academic and industry settings, Dr Wong now investigates inflammatory pathways in the brains of individuals with neurodegenerative diseases, focusing on the development of small molecule screens and therapeutics aimed at mitigating disease aetiology.